In recent decades, the healthcare burden of Cancer increasing rapidly with an increasing incidence rate. The massive investment in research and development has been implemented to find innovative drugs/therapy/Immuno oncology solutions to cure cancer. Some of them gaining interest include oncolytic viruses therapy, stem cell therapies, adoptive cell therapies, etc. Treatment-related off-target effects, side effects, and drug resistance hamper the efficacies of many therapeutic options. Therefore, scientists are working to develop new, effective therapies with low or no toxicity in normal cells. Oncolytic viruses therapy has shown immense opportunities and potential to be tapped in the future to enhance the cancer treatment. Immunotherapy with oncolytic viruses would definitely build survival solutions with significant importance.
The global oncolytic viruses therapy market is segmented on the basis of product, application, and region. Based on the products, the market is divided into Adenoviruses, Herpes Simplex Virus, Vesicular Stomatitis Virus, Vaccinia Virus, and Newcastle Disease Virus. On the basis of application type, the market is segmented into Breast Cancer, Prostate Cancer, Melanoma, Ovarian Cancer, and Others. Based on region, the market is studied across North America, Asia-Pacific, Europe, and LAMEA. Among that, Europe held the largest share of the oncolytic viruses therapy market, followed by America and Asia Pacific. On the other hand, North America is expected to dominate the oncolytic viruses therapy market during the analysis of the forecast period.
The key players of this market include Provectus Biopharmaceuticals, Inc., Takara Bio Inc., SillaJen, Inc., Oncorus, Inc., Amgen, OncoMyx Therapeutics, Inc., Replimune Inc., Oncolytics Biotech, Vyriad, Inc., Viralytics, Transgene SA, OncolysBioPharma, Unleash ImmunoOncolytics, Inc., TargovaxPsiOxus Therapeutics, Sorrento Therapeutics, Lokon Pharma AB, Genelux Corporation, TILT Biotherapeutics, Cold Genesys and Western Oncolytics.